The Lipoprotein(a) Implementation Gap: Bridging Evidence and Clinical Practice.

Area of Science:

• Cardiovascular Medicine
• Genetics
• Pharmacology

Background:

• Lipoprotein(a) [Lp(a)] is a genetically determined cardiovascular risk factor impacting 20% of the global population.
• Despite strong evidence of its importance, clinical screening for Lp(a) remains below 1%, representing a significant implementation gap.
• Persistent barriers include reimbursement issues, provider knowledge gaps, and laboratory standardization challenges.

Purpose of the Study:

• To review the transformation of Lp(a) from an untreatable genetic risk factor to a promising therapeutic target.
• To examine the evidence establishing Lp(a) as both a biomarker and a causal factor in cardiovascular disease.
• To outline a practical management algorithm integrating current risk stratification with emerging therapies.

Main Methods:

• Review of observational studies and Mendelian randomization to establish Lp(a)'s causal role in cardiovascular diseases.
• Examination of novel RNA-targeted therapies demonstrating significant Lp(a) reduction.
• Development of a management algorithm based on Lp(a) levels and emerging therapeutic interventions.

Main Results:

• Elevated Lp(a) is causally linked to coronary heart disease, large-artery stroke, peripheral artery disease, and aortic stenosis.
• Novel therapies achieve 80-95% reductions in Lp(a) levels.
• Phase 3 cardiovascular outcome trials are ongoing to confirm clinical benefits of Lp(a) lowering.

Conclusions:

• Lipoprotein(a) management is evolving from a genetic burden to a treatable condition through targeted therapies.
• Closing the implementation gap for Lp(a) measurement and treatment is crucial for precision cardiovascular medicine.
• Genetic insights and technological innovation are transforming the approach to cardiovascular risk management.